• By ICR Secretariat
  • Posted Wednesday, January 15, 2020

GSK's plan to take over the HIV drug market hasn't worked out

https://www.biopharmadive.com/news/gsks-hiv-two-drug-strategy-challenges-gilead/569852/

British drug giant GlaxoSmithKline wants to claim a larger piece of the HIV drug market. Its strategy: convince patients, doctors and insurance providers that treatments made up of two drugs are better than those made up of three.